IceCure Medical has entered into an exclusive distribution agreement with MTS Medical Technology. The new agreement will accelerate commercialization of its CE-cleared, next generation liquid-nitrogen-based cryoablation system, ProSense® and its consumables, for the treatment of benign and malignant tumors in the fields of breast and interventional oncology, including kidney, bone and lung cancer, in Germany.